Skip to main content
Top
Published in: Annals of Hematology 12/2014

01-12-2014 | Original Article

Enhancement of the cytotoxic activity of cytokine-induced killer cells transfected with IL3PE38KDEL gene against acute myeloid leukemia cells

Authors: Yan Shen, Qi Liu, Yun Luo, Ping Zhang, FengXia Bai, ShiDi Cheng, ShiFeng Lou

Published in: Annals of Hematology | Issue 12/2014

Login to get access

Abstract

Cytokine-induced killer (CIK) cells, one of the feasible and effective methods of adoptive immunotherapy, have shown anti-leukemia activity in vivo and in vitro. But the strategy exhibits limited cytotoxic activity in clinical studies. In this study, CIK cells were transfected with an interleukin-3/Pseudomonas exotoxin gene (IL3PE38KDEL). RT-PCR and ELISA were used to verify the expression of IL3PE38KDEL in the transfected CIK cells. These cells released 1,186.7 ± 149.6 pg IL3PE38KDEL/104 cells over 48 h into the medium and the culture supernatant selectively killed IL3 receptor(IL3R)-positive HL60 cells, but not IL3R-negative K562 cells. Moreover, IL3PE38KDEL transfection did not influence phenotypes and cytokine production of CIK cells. Co-cultured with leukemia cells, IL3PE38KDEL transfected CIK cells showed enhanced cytotoxicity against IL3R-positive HL60 cells at all effector-to-target (E:T) ratios, but exerted a basal anti-leukemia activity against IL3R-negative K562 cells. Our findings demonstrate that IL3PE38KDEL gene transfection may be a novel strategy for improving anti-leukemia activity of CIK cells.
Literature
2.
go back to reference Introna M, Borleri G, Conti E, Franceschetti M, Barbui AM, Broady R, Dander E, Gaipa G, D'Amico G, Biagi E, Parma M, Pogliani EM, Spinelli O, Baronciani D, Grassi A, Golay J, Barbui T, Biondi A, Rambaldi A (2007) Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. Haematologica 92(7):952–959PubMedCrossRef Introna M, Borleri G, Conti E, Franceschetti M, Barbui AM, Broady R, Dander E, Gaipa G, D'Amico G, Biagi E, Parma M, Pogliani EM, Spinelli O, Baronciani D, Grassi A, Golay J, Barbui T, Biondi A, Rambaldi A (2007) Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. Haematologica 92(7):952–959PubMedCrossRef
3.
go back to reference Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL (1991) Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 174(1):139–149PubMedCrossRef Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL (1991) Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 174(1):139–149PubMedCrossRef
4.
go back to reference Burnett AK, Hills RK, Milligan DW, Goldstone AH, Prentice AG, McMullin MF, Duncombe A, Gibson B, Wheatley K (2010) Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. J Clin Oncol Off J Am Soc Clin Oncol 28(4):586–595. doi:10.1200/jco.2009.22.9088 CrossRef Burnett AK, Hills RK, Milligan DW, Goldstone AH, Prentice AG, McMullin MF, Duncombe A, Gibson B, Wheatley K (2010) Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. J Clin Oncol Off J Am Soc Clin Oncol 28(4):586–595. doi:10.​1200/​jco.​2009.​22.​9088 CrossRef
5.
go back to reference Litzow MR, Othus M, Cripe LD, Gore SD, Lazarus HM, Lee SJ, Bennett JM, Paietta EM, Dewald GW, Rowe JM, Tallman MS (2010) Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group. Br J Haematol 148(2):217–225. doi:10.1111/j.1365-2141.2009.07917.x PubMedCentralPubMedCrossRef Litzow MR, Othus M, Cripe LD, Gore SD, Lazarus HM, Lee SJ, Bennett JM, Paietta EM, Dewald GW, Rowe JM, Tallman MS (2010) Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group. Br J Haematol 148(2):217–225. doi:10.​1111/​j.​1365-2141.​2009.​07917.​x PubMedCentralPubMedCrossRef
6.
go back to reference Leemhuis T, Wells S, Scheffold C, Edinger M, Negrin RS (2005) A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 11(3):181–187. doi:10.1016/j.bbmt.2004.11.019 CrossRef Leemhuis T, Wells S, Scheffold C, Edinger M, Negrin RS (2005) A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 11(3):181–187. doi:10.​1016/​j.​bbmt.​2004.​11.​019 CrossRef
7.
go back to reference Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y, Kakizoe T (2000) Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 356(9232):802–807. doi:10.1016/s0140-6736(00)02654-4 PubMedCrossRef Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y, Kakizoe T (2000) Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 356(9232):802–807. doi:10.​1016/​s0140-6736(00)02654-4 PubMedCrossRef
8.
go back to reference Schmidt-Wolf IG, Finke S, Trojaneck B, Denkena A, Lefterova P, Schwella N, Heuft HG, Prange G, Korte M, Takeya M, Dorbic T, Neubauer A, Wittig B, Huhn D (1999) Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer 81(6):1009–1016. doi:10.1038/sj.bjc.6690800 PubMedCentralPubMedCrossRef Schmidt-Wolf IG, Finke S, Trojaneck B, Denkena A, Lefterova P, Schwella N, Heuft HG, Prange G, Korte M, Takeya M, Dorbic T, Neubauer A, Wittig B, Huhn D (1999) Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer 81(6):1009–1016. doi:10.​1038/​sj.​bjc.​6690800 PubMedCentralPubMedCrossRef
9.
go back to reference Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA (1982) Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 155(6):1823–1841PubMedCrossRef Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA (1982) Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 155(6):1823–1841PubMedCrossRef
10.
go back to reference Kalinski P, Nakamura Y, Watchmaker P, Giermasz A, Muthuswamy R, Mailliard RB (2006) Helper roles of NK and CD8+ T cells in the induction of tumor immunity. Polarized dendritic cells as cancer vaccines. Immunol Res 36(1–3):137–146. doi:10.1385/ir:36:1:137 PubMedCrossRef Kalinski P, Nakamura Y, Watchmaker P, Giermasz A, Muthuswamy R, Mailliard RB (2006) Helper roles of NK and CD8+ T cells in the induction of tumor immunity. Polarized dendritic cells as cancer vaccines. Immunol Res 36(1–3):137–146. doi:10.​1385/​ir:​36:​1:​137 PubMedCrossRef
12.
go back to reference Lu PH, Negrin RS (1994) A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol (Baltimore, Md: 1950) 153(4):1687–1696 Lu PH, Negrin RS (1994) A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol (Baltimore, Md: 1950) 153(4):1687–1696
13.
go back to reference Pievani A, Borleri G, Pende D, Moretta L, Rambaldi A, Golay J, Introna M (2011) Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. Blood 118(12):3301–3310. doi:10.1182/blood-2011-02-336321 PubMedCrossRef Pievani A, Borleri G, Pende D, Moretta L, Rambaldi A, Golay J, Introna M (2011) Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. Blood 118(12):3301–3310. doi:10.​1182/​blood-2011-02-336321 PubMedCrossRef
14.
go back to reference Mehta BA, Schmidt-Wolf IG, Weissman IL, Negrin RS (1995) Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+ CD56+ killer cells. Blood 86(9):3493–3499PubMed Mehta BA, Schmidt-Wolf IG, Weissman IL, Negrin RS (1995) Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+ CD56+ killer cells. Blood 86(9):3493–3499PubMed
16.
go back to reference Jiang J, Xu N, Wu C, Deng H, Lu M, Li M, Xu B, Wu J, Wang R, Xu J, Nilsson-Ehle P (2006) Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells. Anticancer Res 26(3B):2237–2242PubMed Jiang J, Xu N, Wu C, Deng H, Lu M, Li M, Xu B, Wu J, Wang R, Xu J, Nilsson-Ehle P (2006) Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells. Anticancer Res 26(3B):2237–2242PubMed
17.
go back to reference Helms MW, Prescher JA, Cao YA, Schaffert S, Contag CH (2010) IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy. Cancer Immunol Immunother CII 59(9):1325–1334. doi:10.1007/s00262-010-0860-y CrossRef Helms MW, Prescher JA, Cao YA, Schaffert S, Contag CH (2010) IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy. Cancer Immunol Immunother CII 59(9):1325–1334. doi:10.​1007/​s00262-010-0860-y CrossRef
18.
go back to reference Niu Q, Wang W, Li Y, Qin S, Wang Y, Wan G, Guan J, Zhu W (2011) Cord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemotherapy in the treatment of advanced solid malignancies. Int Immunopharmacol 11(4):449–456. doi:10.1016/j.intimp.2010.12.014 PubMedCrossRef Niu Q, Wang W, Li Y, Qin S, Wang Y, Wan G, Guan J, Zhu W (2011) Cord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemotherapy in the treatment of advanced solid malignancies. Int Immunopharmacol 11(4):449–456. doi:10.​1016/​j.​intimp.​2010.​12.​014 PubMedCrossRef
19.
go back to reference Chen Y, Lou SF, Deng JC (2009) Construction and prokaryotic expression of fusion gene IL 3-PE38KDEL. J Chongqing Med Univ 34(8):1028–1031 Chen Y, Lou SF, Deng JC (2009) Construction and prokaryotic expression of fusion gene IL 3-PE38KDEL. J Chongqing Med Univ 34(8):1028–1031
20.
go back to reference Frankel AE, Ramage J, Kiser M, Alexander R, Kucera G, Miller MS (2000) Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor. Protein Eng 13(8):575–581PubMedCrossRef Frankel AE, Ramage J, Kiser M, Alexander R, Kucera G, Miller MS (2000) Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor. Protein Eng 13(8):575–581PubMedCrossRef
21.
go back to reference Foss FM, Borkowski TA, Gilliom M, Stetler-Stevenson M, Jaffe ES, Figg WD, Tompkins A, Bastian A, Nylen P, Woodworth T et al (1994) Chimeric fusion protein toxin DAB486IL-2 in advanced mycosis fungoides and the Sezary syndrome: correlation of activity and interleukin-2 receptor expression in a phase II study. Blood 84(6):1765–1774PubMed Foss FM, Borkowski TA, Gilliom M, Stetler-Stevenson M, Jaffe ES, Figg WD, Tompkins A, Bastian A, Nylen P, Woodworth T et al (1994) Chimeric fusion protein toxin DAB486IL-2 in advanced mycosis fungoides and the Sezary syndrome: correlation of activity and interleukin-2 receptor expression in a phase II study. Blood 84(6):1765–1774PubMed
22.
go back to reference Bai FX, Lou SF, Zen HQ, Liao LL (2011) Effect of Recombinant fusion protein IL-3-PE38KDEL on Proliferation and apoptosis of acute myelocytic leukemia cells. Chin J Biol 24(2):179–183 Bai FX, Lou SF, Zen HQ, Liao LL (2011) Effect of Recombinant fusion protein IL-3-PE38KDEL on Proliferation and apoptosis of acute myelocytic leukemia cells. Chin J Biol 24(2):179–183
23.
25.
go back to reference Introna M, Franceschetti M, Ciocca A, Borleri G, Conti E, Golay J, Rambaldi A (2006) Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantation. Bone Marrow Transplant 38(9):621–627. doi:10.1038/sj.bmt.1705503 PubMedCrossRef Introna M, Franceschetti M, Ciocca A, Borleri G, Conti E, Golay J, Rambaldi A (2006) Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantation. Bone Marrow Transplant 38(9):621–627. doi:10.​1038/​sj.​bmt.​1705503 PubMedCrossRef
26.
go back to reference Linn YC, Lau LC, Hui KM (2002) Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts. Br J Haematol 116(1):78–86PubMedCrossRef Linn YC, Lau LC, Hui KM (2002) Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts. Br J Haematol 116(1):78–86PubMedCrossRef
27.
go back to reference Hoyle C, Bangs CD, Chang P, Kamel O, Mehta B, Negrin RS (1998) Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Blood 92(9):3318–3327PubMed Hoyle C, Bangs CD, Chang P, Kamel O, Mehta B, Negrin RS (1998) Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Blood 92(9):3318–3327PubMed
28.
go back to reference Kornacker M, Moldenhauer G, Herbst M, Weilguni E, Tita-Nwa F, Harter C, Hensel M, Ho AD (2006) Cytokine-induced killer cells against autologous CLL: direct cytotoxic effects and induction of immune accessory molecules by interferon-γ. Int J Cancer J Int Cancer 119(6):1377–1382. doi:10.1002/ijc.21994 CrossRef Kornacker M, Moldenhauer G, Herbst M, Weilguni E, Tita-Nwa F, Harter C, Hensel M, Ho AD (2006) Cytokine-induced killer cells against autologous CLL: direct cytotoxic effects and induction of immune accessory molecules by interferon-γ. Int J Cancer J Int Cancer 119(6):1377–1382. doi:10.​1002/​ijc.​21994 CrossRef
29.
30.
go back to reference Liu L, Zhang W, Qi X, Li H, Yu J, Wei S, Hao X, Ren X (2012) Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. Clin Cancer Res Off J Am Assoc Cancer Res 18(6):1751–1759. doi:10.1158/1078-0432.ccr-11-2442 CrossRef Liu L, Zhang W, Qi X, Li H, Yu J, Wei S, Hao X, Ren X (2012) Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. Clin Cancer Res Off J Am Assoc Cancer Res 18(6):1751–1759. doi:10.​1158/​1078-0432.​ccr-11-2442 CrossRef
31.
go back to reference Hara T, Miyajima A (1992) Two distinct functional high affinity receptors for mouse interleukin-3 (IL-3). EMBO J 11(5):1875–1884PubMedCentralPubMed Hara T, Miyajima A (1992) Two distinct functional high affinity receptors for mouse interleukin-3 (IL-3). EMBO J 11(5):1875–1884PubMedCentralPubMed
32.
go back to reference Biagi E, Marin V, Giordano Attianese GM, Dander E, D'Amico G, Biondi A (2007) Chimeric T-cell receptors: new challenges for targeted immunotherapy in hematologic malignancies. Haematologica 92(3):381–388PubMedCrossRef Biagi E, Marin V, Giordano Attianese GM, Dander E, D'Amico G, Biondi A (2007) Chimeric T-cell receptors: new challenges for targeted immunotherapy in hematologic malignancies. Haematologica 92(3):381–388PubMedCrossRef
33.
go back to reference Jin L, Lee EM, Ramshaw HS, Busfield SJ, Peoppl AG, Wilkinson L, Guthridge MA, Thomas D, Barry EF, Boyd A, Gearing DP, Vairo G, Lopez AF, Dick JE, Lock RB (2009) Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell 5(1):31–42. doi:10.1016/j.stem.2009.04.018 PubMedCrossRef Jin L, Lee EM, Ramshaw HS, Busfield SJ, Peoppl AG, Wilkinson L, Guthridge MA, Thomas D, Barry EF, Boyd A, Gearing DP, Vairo G, Lopez AF, Dick JE, Lock RB (2009) Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell 5(1):31–42. doi:10.​1016/​j.​stem.​2009.​04.​018 PubMedCrossRef
34.
go back to reference Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M (2010) Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther J Am Soc Gene Ther 18(4):666–668. doi:10.1038/mt.2010.31 CrossRef Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M (2010) Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther J Am Soc Gene Ther 18(4):666–668. doi:10.​1038/​mt.​2010.​31 CrossRef
35.
go back to reference Gal H, Amariglio N, Trakhtenbrot L, Jacob-Hirsh J, Margalit O, Avigdor A, Nagler A, Tavor S, Ein-Dor L, Lapidot T, Domany E, Rechavi G, Givol D (2006) Gene expression profiles of AML derived stem cells; similarity to hematopoietic stem cells. Leukemia 20(12):2147–2154. doi:10.1038/sj.leu.2404401 PubMedCrossRef Gal H, Amariglio N, Trakhtenbrot L, Jacob-Hirsh J, Margalit O, Avigdor A, Nagler A, Tavor S, Ein-Dor L, Lapidot T, Domany E, Rechavi G, Givol D (2006) Gene expression profiles of AML derived stem cells; similarity to hematopoietic stem cells. Leukemia 20(12):2147–2154. doi:10.​1038/​sj.​leu.​2404401 PubMedCrossRef
36.
go back to reference van Rhenen A, Moshaver B, Kelder A, Feller N, Nieuwint AW, Zweegman S, Ossenkoppele GJ, Schuurhuis GJ (2007) Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission. Leukemia 21(8):1700–1707. doi:10.1038/sj.leu.2404754 PubMedCrossRef van Rhenen A, Moshaver B, Kelder A, Feller N, Nieuwint AW, Zweegman S, Ossenkoppele GJ, Schuurhuis GJ (2007) Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission. Leukemia 21(8):1700–1707. doi:10.​1038/​sj.​leu.​2404754 PubMedCrossRef
37.
go back to reference Allured VS, Collier RJ, Carroll SF, McKay DB (1986) Structure of exotoxin A of Pseudomonas aeruginosa at 3.0-Angstrom resolution. Proc Natl Acad Sci U S A 83(5):1320–1324PubMedCentralPubMedCrossRef Allured VS, Collier RJ, Carroll SF, McKay DB (1986) Structure of exotoxin A of Pseudomonas aeruginosa at 3.0-Angstrom resolution. Proc Natl Acad Sci U S A 83(5):1320–1324PubMedCentralPubMedCrossRef
38.
go back to reference Hwang J, Fitzgerald DJ, Adhya S, Pastan I (1987) Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli. Cell 48(1):129–136PubMedCrossRef Hwang J, Fitzgerald DJ, Adhya S, Pastan I (1987) Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli. Cell 48(1):129–136PubMedCrossRef
39.
go back to reference Kreitman RJ, Pastan I (1995) Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor. Biochem J 307(Pt 1):29–37PubMedCentralPubMed Kreitman RJ, Pastan I (1995) Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor. Biochem J 307(Pt 1):29–37PubMedCentralPubMed
40.
go back to reference Crittenden M, Gough M, Chester J, Kottke T, Thompson J, Ruchatz A, Clackson T, Cosset FL, Chong H, Diaz RM, Harrington K, Alvarez Vallina L, Vile R (2003) Pharmacologically regulated production of targeted retrovirus from T cells for systemic antitumor gene therapy. Cancer Res 63(12):3173–3180PubMed Crittenden M, Gough M, Chester J, Kottke T, Thompson J, Ruchatz A, Clackson T, Cosset FL, Chong H, Diaz RM, Harrington K, Alvarez Vallina L, Vile R (2003) Pharmacologically regulated production of targeted retrovirus from T cells for systemic antitumor gene therapy. Cancer Res 63(12):3173–3180PubMed
42.
go back to reference Vallera DA, Jin N, Baldrica JM, Panoskaltsis-Mortari A, Chen SY, Blazar BR (2000) Retroviral immunotoxin gene therapy of acute myelogenous leukemia in mice using cytotoxic T cells transduced with an interleukin 4/diphtheria toxin gene. Cancer Res 60(4):976–984PubMed Vallera DA, Jin N, Baldrica JM, Panoskaltsis-Mortari A, Chen SY, Blazar BR (2000) Retroviral immunotoxin gene therapy of acute myelogenous leukemia in mice using cytotoxic T cells transduced with an interleukin 4/diphtheria toxin gene. Cancer Res 60(4):976–984PubMed
43.
go back to reference Chen SY, Yang AG, Chen JD, Kute T, King CR, Collier J, Cong Y, Yao C, Huang XF (1997) Potent antitumour activity of a new class of tumour-specific killer cells. Nature 385(6611):78–80. doi:10.1038/385078a0 PubMedCrossRef Chen SY, Yang AG, Chen JD, Kute T, King CR, Collier J, Cong Y, Yao C, Huang XF (1997) Potent antitumour activity of a new class of tumour-specific killer cells. Nature 385(6611):78–80. doi:10.​1038/​385078a0 PubMedCrossRef
44.
go back to reference Hu CC, Ke YQ, Sun XL, Jiang XD, Xu RX, Lv J, Wang YS, Cai YQ, Qin LS, Zou YX (2009) Human mesenchymal stem cells-like cells as cellular vehicles for delivery of immunotoxin in vitro. Biotechnol Lett 31(2):181–189. doi:10.1007/s10529-008-9860-9 PubMedCrossRef Hu CC, Ke YQ, Sun XL, Jiang XD, Xu RX, Lv J, Wang YS, Cai YQ, Qin LS, Zou YX (2009) Human mesenchymal stem cells-like cells as cellular vehicles for delivery of immunotoxin in vitro. Biotechnol Lett 31(2):181–189. doi:10.​1007/​s10529-008-9860-9 PubMedCrossRef
45.
go back to reference Jia J, Li H, Tai S, Lv M, Liao M, Yang Z, Zhang B, Zhou B, Zhang G, Zhang L (2008) Construction and preliminary investigation of a plasmid containing a novel immunotoxin DT390-IL-18 gene for the prevention of murine experimental autoimmune encephalomyelitis. DNA Cell Biol 27(5):279–285. doi:10.1089/dna.2007.0642 PubMedCrossRef Jia J, Li H, Tai S, Lv M, Liao M, Yang Z, Zhang B, Zhou B, Zhang G, Zhang L (2008) Construction and preliminary investigation of a plasmid containing a novel immunotoxin DT390-IL-18 gene for the prevention of murine experimental autoimmune encephalomyelitis. DNA Cell Biol 27(5):279–285. doi:10.​1089/​dna.​2007.​0642 PubMedCrossRef
46.
go back to reference Wang S, Zhu G, Chapoval AI, Dong H, Tamada K, Ni J, Chen L (2000) Costimulation of T cells by B7-H2, a B7-like molecule that binds ICOS. Blood 96(8):2808–2813PubMed Wang S, Zhu G, Chapoval AI, Dong H, Tamada K, Ni J, Chen L (2000) Costimulation of T cells by B7-H2, a B7-like molecule that binds ICOS. Blood 96(8):2808–2813PubMed
47.
go back to reference Lopez RD, Waller EK, Lu PH, Negrin RS (2001) CD58/LFA-3 and IL-12 provided by activated monocytes are critical in the in vitro expansion of CD56+ T cells. Cancer Immunol Immunother CII 49(12):629–640CrossRef Lopez RD, Waller EK, Lu PH, Negrin RS (2001) CD58/LFA-3 and IL-12 provided by activated monocytes are critical in the in vitro expansion of CD56+ T cells. Cancer Immunol Immunother CII 49(12):629–640CrossRef
48.
go back to reference Marten A, Renoth S, von Lilienfeld-Toal M, Buttgereit P, Schakowski F, Glasmacher A, Sauerbruch T, Schmidt-Wolf IG (2001) Enhanced lytic activity of cytokine-induced killer cells against multiple myeloma cells after co-culture with idiotype-pulsed dendritic cells. Haematologica 86(10):1029–1037PubMed Marten A, Renoth S, von Lilienfeld-Toal M, Buttgereit P, Schakowski F, Glasmacher A, Sauerbruch T, Schmidt-Wolf IG (2001) Enhanced lytic activity of cytokine-induced killer cells against multiple myeloma cells after co-culture with idiotype-pulsed dendritic cells. Haematologica 86(10):1029–1037PubMed
51.
go back to reference Schmidt-Wolf IG, Lefterova P, Mehta BA, Fernandez LP, Huhn D, Blume KG, Weissman IL, Negrin RS (1993) Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol 21(13):1673–1679PubMed Schmidt-Wolf IG, Lefterova P, Mehta BA, Fernandez LP, Huhn D, Blume KG, Weissman IL, Negrin RS (1993) Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol 21(13):1673–1679PubMed
Metadata
Title
Enhancement of the cytotoxic activity of cytokine-induced killer cells transfected with IL3PE38KDEL gene against acute myeloid leukemia cells
Authors
Yan Shen
Qi Liu
Yun Luo
Ping Zhang
FengXia Bai
ShiDi Cheng
ShiFeng Lou
Publication date
01-12-2014
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 12/2014
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-014-2146-5

Other articles of this Issue 12/2014

Annals of Hematology 12/2014 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.